Palmitoylation Regulates Regulators of G-protein Signaling (RGS) 16 Function

I. MUTATION OF AMINO-TERMINAL CYSTEINE RESIDUES ON RGS16 PREVENTS ITS TARGETING TO LIPID RAFTS AND PALMITOYLATION OF AN INTERNAL CYSTEINE RESIDUE*

Abel Hiol § {ddagger}, Penelope C. Davey § {ddagger}, James L. Osterhout ¶, Abdul A. Waheed {ddagger}, Elizabeth R. Fischer ||, Ching-Kang Chen **, Graeme Milligan {ddagger}{ddagger}, Kirk M. Druey ¶ and Teresa L. Z. Jones {ddagger} §§

From the {ddagger} Metabolic Diseases Branch, NIDDK, National Institutes of Health, Bethesda, Maryland 20892, Scotland, United Kingdom, Molecular Signal Transduction Section, Laboratory of Allergic Diseases, NIAID, National Institutes of Health, Rockville, Maryland 20892, Scotland, United Kingdom, || Microscopy Branch, NIAID, National Institutes of Health, Hamilton, Montana 59840, Scotland, United Kingdom, ** Department of Ophthalmology, University of Utah, Salt Lake, Utah 84112, Scotland, United Kingdom, {ddagger}{ddagger} Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom

Received for publication, October 3, 2002 , and in revised form, March 16, 2003.
    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Regulators of G-protein signaling (RGS) proteins down-regulate signaling by heterotrimeric G-proteins by accelerating GTP hydrolysis on the G{alpha} subunits. Palmitoylation, the reversible addition of palmitate to cysteine residues, occurs on several RGS proteins and is critical for their activity. For RGS16, mutation of Cys-2 and Cys-12 blocks its incorporation of [3H]palmitate and ability to turn-off Gi and Gq signaling and significantly inhibited its GTPase activating protein activity toward aG{alpha} subunit fused to the 5-hydroxytryptamine receptor 1A, but did not reduce its plasma membrane localization based on cell fractionation studies and immunoelectron microscopy. Palmitoylation can target proteins, including many signaling proteins, to membrane microdomains, called lipid rafts. A subpopulation of endogenous RGS16 in rat liver membranes and overexpressed RGS16 in COS cells, but not the nonpalmitoylated cysteine mutant of RGS16, localized to lipid rafts. However, disruption of lipid rafts by treatment with methyl-{beta}-cyclodextrin did not decrease the GTPase activating protein activity of RGS16. The lipid raft fractions were enriched in protein acyltransferase activity, and RGS16 incorporated [3H]palmitate into a peptide fragment containing Cys-98, a highly conserved cysteine within the RGS box. These results suggest that the amino-terminal palmitoylation of an RGS protein promotes its lipid raft targeting that allows palmitoylation of a poorly accessible cysteine residue that we show in the accompanying article (Osterhout, J. L., Waheed, A. A., Hiol, A., Ward, R. J., Davey, P. C., Nini, L., Wang, J., Milligan, G., Jones, T. L. Z., and Druey, K. M. (2003) J. Biol. Chem. 278, 19309-19316) was critical for RGS16 and RGS4 GAP activity.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Heterotrimeric G proteins transmit extracellular signals by coupling cell surface receptors to intracellular effectors (1, 2). The heterotrimer consists of G{alpha} subunits that bind GDP/GTP and G{beta}{gamma} subunits that form a hydrophobic complex. Upon activation by a receptor, the G{alpha} subunit exchanges GDP for GTP and in this active state modulates effectors. Regulators of G-protein signaling (RGS)1 proteins bind to G{alpha} subunits during GTP hydrolysis and accelerate GTP hydrolysis. RGS proteins are a family of over 20 proteins that share significant homology in a domain called the RGS box that binds the G{alpha} subunit (3, 4, 5). This family of proteins can be subdivided on the basis of other domains outside the RGS box. RGS16 shares significant homology with RGS4 and RGS5 and consists of short amino- and carboxyl-terminal ends on either side of the RGS box. RGS16 is expressed in several tissues including retina, pituitary, and liver (6, 7). Despite considerable knowledge about the in vitro function of RGS proteins, the intracellular regulation of these proteins is poorly understood.

Several RGS proteins undergo palmitoylation, the reversible addition of palmitate to cysteine residues through a thioester bond (8, 9, 10, 11, 12, 13). Palmitoylation increases the hydrophobicity and stabilizes the membrane binding of proteins, but is not necessarily required for membrane attachment, as is the case for RGS16 and RGS4 (9, 12, 14). Palmitoylation can also directly affect protein interactions. Several RGS proteins have GTPase activating protein (GAP) activity for only the nonpalmitoylated form of G{alpha} subunits (15). In addition, palmitoylation of RGS4 and RGS10 inhibits their GAP activity toward G{alpha}-GTP in solution-based assays, but decreased and increased, respectively, agonist-stimulated GTPase activity in phospholipid vesicles containing a receptor and G-protein (13).

Acylation can also target proteins to membrane microdomains enriched in cholesterol and sphingolipids (16, 17). These microdomains, called lipid rafts, can be isolated by their resistance to cold, nonionic detergent extraction and buoyancy on gradient centrifugation. Compartmentalization of several signal transduction pathways and proteins, including G-proteins, occurs in lipid rafts (18, 19, 20). Disruption of lipid rafts prevents signaling in many, but not all (21) of these pathways. For RGS proteins, RGS9 in a complex with G{beta}5 translocates to lipid rafts after activation of photoreceptor outer segments by illumination (22). RGS7 shows resistance to detergent extraction, but does not segregate with caveolin, a resident protein of lipid rafts, after gradient centrifugation (8). The lipid raft localization of other RGS proteins has not been reported. Besides being the home of acylated proteins, lipid rafts are also enriched in protein acyltransferase (PAT) activity (23).

Previously, we reported that amino-terminal cysteine residues on RGS16 were critical for its palmitoylation and ability to turn-off G-protein signaling in vivo, but not for its ability to act as a GTPase activating protein for G{alpha} subunits in a solution-based assay (9). Here, we investigated the action of palmitoylation for RGS16 function and found that mutation of the amino-terminal cysteine residues and the loss of palmitoylation changed the targeting of RGS16 from lipid rafts and prevented the incorporation of [3H]palmitate into a cysteine residue in the RGS box. In the accompanying article (24) we show that this cysteine residue was critical for RGS16 function in the cell and palmitoylation on this internal cysteine residue markedly improved the GAP activity of RGS16.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Plasmid Constructs and Protein Purification—The cDNA for mouse RGS16 was inserted into the pcDNA3 vector (Invitrogen). Cysteine to alanine mutations for residues 2 and 12 in RGS16 were described previously (9). The cDNA for human RGS16 was inserted into the pcDNA3 vector with the DNA sequence for the hemagglutinin epitope in-frame at the 5' end of the cDNA for RGS16. Mutation of Cys-98 in HA-RGS16 was performed using the QuikChange mutagenesis kit (Stratagene). Construction of the pcDNA3 vector containing the cDNA for the 5-hydroxytryptamine (serotonin) receptor subtype 1A fused in-frame to the pertussis toxin-resistant mutant of G{alpha}o1 (Cys-351, the site of ADP-ribosylation by pertussis toxin, mutated to glycine) (5-HT1A/G{alpha}o1) was described previously (25). A glutathione S-transferase-RGS16 fusion protein was produced in Escherichia coli as previously described (9) and purified on glutathione-Sepharose as per the manufacturer's instructions (Amersham Biosciences). RGS16 was cleaved from glutathione S-transferase using biotinylated thrombin and then separated from thrombin using streptavidin-agarose (Novagen). Purified proteins were dialyzed against 50 mM Tris, pH 8, 100 mM NaC1, 1 mM EDTA, and 5% (v/v) glycerol and stored at -80 °C.

Cell Culture, Transfection, and Metabolic Labeling—Stable transfection of HEK293 cells with the plasmid containing the 5-HT1A/G{alpha}o1 fusion protein was performed and the cells maintained as described (25). COS-7 and HEK293 cells were transfected using 10 µg of DNA in 75-cm2 flasks using LipofectAMINE (Invitrogen) and Superfect (Qiagen), respectively. 48 h after transfection, the cells were either harvested directly or prepared for radiolabeling by a 2-h incubation in serum-free Dulbecco's modified Eagle's medium for [3H]palmitate labeling or in the same media without methionine for [35S]methionine labeling. The cells were then incubated for 1 h in serum-free medium containing 500 µCi/ml [3H]palmitic acid (American Radiolabeled Chemicals, specific activity 60 Ci/mmol), 50 µg/ml cycloheximide, and 1% (v/v) dimethyl sulfoxide or serum-free medium without methionine containing 250 µCi/ml Met-35S-Label (American Radiolabeled Chemicals). The cells were harvested in cold phosphate-buffered saline (PBS), and cell pellets were obtained by centrifugation at 2,000 x g for 10 min and stored at -80 °C.

Cell Fractionation and Protein Determination—Cell pellets were homogenized and separated into particulate and soluble fractions by centrifugation at 100,000 x g for 1 h as described (26). The protein concentration was determined using the Bio-Rad protein assay kit with immunoglobulin G as the standard.

Immunotechniques and Fluorography—For immunoblotting, proteins were separated by SDS-PAGE and transferred to nitrocellulose paper. Proteins were detected using the CT-265 antiserum raised against purified mouse RGS16 (9), the affinity-purified AS antibody that detects the carboxyl-terminal decapeptide of G{alpha}i (27), an antibody directed against the 5-HT1A receptor (Santa Cruz Biotechnologies) for the 5-HT1A/G{alpha}o1 fusion protein, a monoclonal antibody to the HA epitope (anti-HA.11, Covance Inc.), and antibodies to caveolin (BD Transduction Laboratories) and Na+/K+-ATPase (Biomol Research Laboratories). Antibody binding was detected by enhanced chemiluminescence (Amersham Biosciences). For immunoprecipitation, 500 µg of protein was incubated with 5 µl of the CT-265 antiserum or a polyclonal antibody to the HA epitope (Santa Cruz Biotechnologies) and prepared as described (26) except that after separation by SDS-PAGE, the tritium-labeled proteins were transferred to nitrocellulose membranes. Fluorography was performed by coating the membranes with EA wax (EA Biotech Ltd.) and placing in film cassettes with MS film (Kodak) at -70 °C. The exposure times ranged from 3 to 7 days.

Preparation of Membranes for GTPase Assay—30 h after transfection with plasmids encoding HA-RGS16 (WT or mutants), HEK-293 cells stably expressing the 5-HT1A/G{alpha}o1 were treated overnight with pertussis toxin (50 ng/ml) to eliminate endogenous G{alpha}i/o activity. 48 h after transfection, the cells were scraped and harvested in PBS and centrifuged at 2,000 x g for 10 min at 4 °C. The cell pellet was resuspended in ice-cold TE buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA) and homogenized with 30-50 passages of a Dounce homogenizer followed by 15 passages through a 25-gauge needle. Unbroken cells and debris were pelleted by centrifugation at 4,000 x g for 5 min at 4 °C. The supernatant was centrifuged at 100,000 x g for 30 min at 4 °C to pellet the membrane fraction. Membranes were resuspended in TE buffer to ~2 mg/ml and stored as aliquots at -80 °C.

High Affinity GTPase Assay—Steady state GTPase activity was determined in HEK293 cell membranes expressing the 5-HT1A/G{alpha}o1 fusion protein. Membrane preparations (10 µg of total protein) were stimulated with the indicated concentrations of 5-HT in an ATP-regenerating buffer system (20 mM creatine phosphate, 0.1 units/µl creatine kinase, 200 µM AMP-PNP, 500 µM ATP, 2 mM ouabain, 200 mM NaCl, 10 mM MgCl2, 4 mM dithiothreitol, 200 µM EDTA, pH 7.5, 80 mM Tris, pH 7.5, 1 µM GTP) spiked with 50,000 cpm of [{gamma}-32P]GTP (Amersham Biosciences, 3000 Ci/mmol) and incubated for 20 min at 30 °C. The reactions were stopped by addition of ice-cold 10% (w/v) activated charcoal in 50 mM phosphoric acid followed by centrifugation at 10,000 x g for 20 min at 4 °C. Supernatants containing free [{gamma}-32P]phosphate were analyzed using liquid scintillation spectrometry. Nonspecific GTPase activity was determined in simultaneous reactions containing 100 mM GTP.

Plasma Membrane Isolation—Livers (6-9 g) from male rats, CD strain (Charles River Laboratories), were rapidly excised, washed in homogenization buffer (HB) consisting of 0.25 M sucrose, 5 mM Tris-HCl, pH 7.4, and 1 mM MgCl2, and cut into about 2-3-mm pieces. The rat liver pieces or COS cell pellets were homogenized in 5 volumes of HB by 10 strokes in a Dounce homogenizer, and the liver samples were filtered through four layers of moistened gauze. The COS cell homogenate or the filtered homogenate from liver underwent centrifugation at 3,000 x g for 5 min. The supernatant was saved, and homogenization and centrifugation of the pellet was repeated in half the original volume of HB. The supernatants were combined and centrifuged at 3,000 x g for 10 min. The pellet (total membrane fraction) was suspended to bring the final buffer concentration to 1.42 M sucrose in 5 mM Tris-HCl, pH 7.4, 1 mM MgCl2 in a volume equal to twice the volume of the original homogenate, transferred to a nitrocellulose tube, and overlaid with HB. After centrifugation for 1 h at 120,000 x g in a Beckman SW28 rotor, the material at the interface of 0.25 and 1.42 M sucrose was suspended in HB in a volume equal to four times the initial pellet volume and washed by centrifugation at 3,000 x g for 10 min. The pellet was suspended in buffer consisting of 1.35 M sucrose, 5 mM Tris-HCl, pH 7.4, and 1 mM MgCl2 and underwent centrifugation at 100,000 x g for 150 min. The pellet was washed in HB with centrifugation at 3,000 x g for 10 min. The final pellet (plasma membrane fraction) was suspended in HB at 1.5 mg of protein/ml.

Immunoelectron Microscopy—Subconfluent HEK293T cells were plated on Thermanox coverslips (Nunc, Inc.) and transfected with HA-pCDNA3 or HA-RGS16 plasmids in 12-well tissue culture plates. 24 h post-transfection, cells were rinsed twice with Hank's balanced salt solution before fixation with PLP fixative (28) plus 0.25% electron microscopy grade glutaraldehyde for 2 h. All incubations were done at room temperature. After 2 rinses with PBS, cells were permeabilized with PBS, 0.01% saponin and incubated with or without primary antibody (anti-HA.11, Covance) diluted 1:500 in PBS, 0.01% saponin for 1 h. The secondary antibody, Nanogold-conjugated goat anti-mouse IgG (Nanoprobes, Inc.), was diluted 1:50 in PBS, 0.01% saponin and incubated with cells for an additional 1 h. After washing with PBS, the samples were fixed overnight at 4 °C in 2.5% glutaraldehyde, 4% paraformaldehyde in 0.1 M sodium cacodylate buffer, washed three times for 5 min each with dH2O, and then the Nanogold was silver enhanced for 4 min with HQ Silver Reagents (Nanoprobes, Inc.). The samples were post-fixed for 30 min with 1% osmium tetroxide, 0.8% potassium ferricyanide in 0.1 M sodium cacodylate, washed with dH2O, dehydrated in a graded ethanol series, and embedded in Spurr's resin. Thin sections were cut with an RMC MT-7000 ultramicrotome (Boeckeler, Tucson, AZ) stained with 1% uranyl acetate and observed at 80 kV on a Philips CM-10 transmission electron microscope (FEI, Hillsboro, OR). Images were acquired with an AMT digital camera (Advanced Microscopy Techniques) and processed using Adobe Photoshop version 7 (Adobe Systems).

Detergent-resistant Membrane (DRM) Partitioning and Cellular Cholesterol Depletion and Determination—Lipid raft isolation was carried out as previously described (29, 30). Briefly, cell pellets from transfected COS or HEK293 cells, or the plasma membrane fraction from rat livers were resuspended and incubated for 20 min at 4 °C in cold buffer containing 0.5% Triton X-100 to give a detergent to protein ratio of 5:1. The samples were adjusted to 35% (v/v) OptiPrep and the DRM fraction separated by centrifugation on a 5/30/35% OptiPrep gradient. For depletion of cellular cholesterol, cells were incubated in serum-free Dulbecco's modified Eagle's medium containing 10 mM methyl-{beta}-cyclodextrin (Sigma) for 30 min and then harvested. The concentration of cholesterol in the cell lysates was determined as described (21).

Protein Acyltransferase Activity—HEK293 cells stably expressing the 5-HT1A/G{alpha}o1 fusion protein were treated with detergent and separated on an OptiPrep gradient as described above except six fractions of 0.78 ml were taken. Three µg of protein from each fraction was incubated for 45 min at 30 °C with 10 µg of purified RGS16, 200 µM coenzyme A, 2 mM ATP, and 1 µl of [9,10-3H]palmitate (American Radiolabeled Chemicals, 30-60 Ci/mmol) in a final volume of 100 µl as described (31). The reaction was stopped by the addition of sample buffer and the proteins separated by SDS-PAGE. The gels were either stained by Microwave-Blue (Protiga, Frederick, MD), or the proteins were transferred to nitrocellulose paper and prepared for fluorography.

Clostripain Treatment—After the final washing step, immunoprecipitates bound to protein A-Sepharose (Amersham Biosciences) were resuspended in 30 µl of a buffer containing 75 mM NaPO4 and 2.5 mM dithiothreitol with and without 1.5 units of clostripain (Sigma) and incubated for 2 h at room temperature. The reaction was stopped by the addition of sample buffer (Novex) and boiling. The peptides were separated by SDS-PAGE on 10-20% Tricine gels (Invitrogen), and prepared for fluorography. MS films (Eastman Kodak) were exposed to the nitrocellulose membranes for 3 days at -70 °C.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
GAP Activity of the C2/12A Mutant after Transfection—In a previous report (9), we found that two amino-terminal cysteine residues (Cys-2 and Cys-12) on RGS16 were critical for palmitoylation and in vivo function, but were not necessary for membrane attachment and in vitro GAP activity. We tested whether the failure of the C2A/C12A mutant to turn-off Gi and Gq signaling was because of the inability of the mutant to accelerate the GTP hydrolysis of the G{alpha} subunit in cellular membranes. To test GAP activity, we used a fusion protein in which the carboxyl terminus of the 5-HT1A receptor is fused to the amino terminus of a mutant form of G{alpha}o1 (C351G) that is resistant to pertussis toxin treatment (25). In HEK293 cells stably expressing the fusion protein, GTPase activity of the fused G{alpha} subunit in response to 5-HT is determined after inactivating endogenous G{alpha}i and G{alpha}o proteins by pertussis toxin. This method reduces GTP turnover of the endogenous G{alpha}i and G{alpha}o proteins, as well as ensuring a 1:1 stoichiometry of receptor to G{alpha} subunit (32). For these experiments, the stably transfected cells expressing the fusion protein were transiently transfected to co-express either the WT RGS16 or the C2A/C12A mutant with a hemagglutinin (HA) epitope tag at the amino terminus. The level of expression of these proteins in the membrane was similar (Fig. 1A). As expected, 5-HT increased GTPase activity in membranes expressing the fusion protein alone (Fig. 1B, open diamonds). Membranes from cells co-expressing WT RGS16 showed a marked additional increase in GTPase activity in response to 5-HT (Fig. 1B, filled circles). The 5-HT-induced GTPase activity in membranes from cells expressing the C2A/C12A mutant was only slightly better than the membranes from the vector-transfected cells (Fig. 1B, filled squares). We tested whether the C2A/C12A mutation itself could affect RGS16 GAP activity by adding purified RGS16 proteins expressed in bacteria to the membranes of the 5-HT1A/G{alpha}o1 fusion protein-expressing cells. Addition of WT RGS16 or RGS16 (C2A/C12A) to the membranes resulted in a nearly identical increase in 5-HT-evoked GTPase activity at each RGS16 concentration (Fig. 1C). These results indicate that the poor function of the nonpalmitoylated C2A/C12A mutant of RGS16 within cells (Fig. 1B) (9) was likely because of altered intracellular processing or targeting.



View larger version (21K):
[in this window]
[in a new window]
 
FIG. 1.
GAP activity of an amino-terminal cysteine mutant of RGS16 after transfection or reconstitution. A and B, HEK293 cells stably expressing a fusion protein between the 5-HT1A receptor and G{alpha}o1 (C351G) were transiently transfected with plasmids containing LacZ, as a control, HA-RGS16 or HA-RGS16 with Cys-2 and Cys-12 mutated to alanine (C2/12A). The cells were pretreated with pertussis toxin to block the activity of the endogenous G{alpha}i and G{alpha}o proteins. 48 h after transfection, membranes were prepared and 50 µg of protein was separated by SDS-PAGE and prepared for immunoblotting with an antibody to the HA epitope (A) or for agonist-stimulated steady-state GTPase activity as determined after addition of the indicated concentrations of 5-HT and incubation for 20 min at 37 °C (B). C, the WT and C2A/C12A mutant of RGS16 were expressed in bacteria, purified, and incubated with membranes of HEK293 cells expressing the 5-HT1A/G{alpha}o1 fusion protein. High-affinity GTPase activity was determined in the presence of 1 µM 5-HT. For panels B and C, values represent the mean ± S.E. of four independent experiments each. For panel A, molecular mass markers in kDa are shown to the left.

 

Plasma Membrane Localization of the WT and Mutant RGS16—We investigated whether palmitoylation was critical for the plasma membrane localization of RGS16 because G protein signaling occurs on the cytoplasmic face of the plasma membrane and other signaling proteins such as G{alpha}13 (33), G{alpha}z (34), H-Ras (35), and p59fyn (36) require palmitoylation for plasma membrane localization. COS cells transfected with the WT RGS16 or the double cysteine mutant, C2A/C12A, were homogenized and subcellular fractions were obtained by gradient centrifugation. Both the WT RGS16 and the nonpalmitoylated C2A/C12A mutant were found to a similar degree in the fraction that was enriched in the plasma membrane protein, Na+/K+-ATPase (Fig. 2). In these experiments, we expressed RGS16 without any epitope tags and used the CT-265 antiserum raised against the whole protein. As in previous experiments (9), we found two bands for RGS16 after separation by SDS-PAGE and immunoblotting with the CT-265 antiserum. These two bands are found in rat liver membranes (Fig. 4A) and after expression of the HA-tagged RGS16 when the CT-265 antiserum is used for detection. The lower band could represent a degradation product missing part of the amino terminus because it is not detected with the HA antibody (Fig. 1A).



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 2.
Plasma membrane localization of the WT and C2A/C12A mutant of RGS16. COS cells were transfected with vector alone or with the cDNAs for the untagged WT and C2A/C12A mutant of RGS16 and harvested 48 h after transfection. Total (TM) and plasma membrane (PM) fractions were obtained by centrifugation as described under "Experimental Procedures." Forty µg of protein from each fraction was separated by SDS-PAGE and immunoblotted with the CT-265 antiserum to RGS16 and an antibody to the Na+/K+-ATPase, a plasma membrane protein. The arrow points to RGS16 and the arrowhead points to Na+/K+-ATPase. The molecular mass markers in kDa are shown to the left of each immunoblot.

 


View larger version (27K):
[in this window]
[in a new window]
 
FIG. 4.
DRM partitioning of RGS16. The plasma membrane fraction from rat livers (A) or the cell pellets from COS cells transiently expressing RGS16 or the C2A/C12A mutant (B) were treated with cold, Triton X-100 and then separated by gradient centrifugation. Fractions were collected starting with fraction 1 from the top and analyzed by SDS-PAGE and immunoblotting with antibodies to the indicated proteins as described under "Experimental Procedures." The arrowhead points to RGS16. The molecular mass markers in kDa are shown to left of the panel.

 

We also used immunoelectron microscopy to determine the intracellular localization of the WT RGS16 and nonpalmitoylated C2A/C12A mutant in HEK293 cells transfected with HA-tagged RGS16. Immunoblotting of cell lysates from HEK293 cells expressing RGS16 proteins with an anti-HA antibody revealed only one band at about 30 kDa (Fig. 1A). Plasma membrane staining was seen for cells expressing the WT RGS16 and the C2A/C12A mutant (Fig. 3, A and B). RGS16-expressing cells incubated without the HA antibody or vector-transfected cells showed only a trivial amount of staining (Fig. 3, C and D). These results indicate that the nonpalmitoylated C2A/C12A mutant was localized to the plasma membrane in mammalian cells as well as WT RGS16. Therefore, the poor function of nonpalmitoylated C2A/C12A mutant of RGS16 cannot be explained simply by mislocalization from the plasma membrane.



View larger version (145K):
[in this window]
[in a new window]
 
FIG. 3.
Intracellular localization of the WT and mutant RGS16 by immunoelectron microscopy. HEK293 cells were transiently transfected with HA-RGS16 (A and D), HA-RGS16 with Cys-2 and Cys-12 mutated to alanine (B) or with vector alone (C). 48 h after transfection the cells were fixed and stained with (A-C) or without (D) anti-HA antibodies, as described under "Experimental Procedures." The HA-tagged RGS proteins are seen as small dense dots predominantly on the cell surface (A and B). The black bar in the bottom right corners corresponds to 500 nm.

 

Lipid Raft Targeting—Another function of palmitoylation is targeting proteins to membrane microdomains, called lipid rafts (16, 17). G{alpha} subunits, including G{alpha}i and G{alpha}q, which are regulated by RGS16, are located in lipid rafts (37, 38). We isolated lipid rafts by treating cells or membranes with cold, Triton X-100 and separating the DRM fraction by OptiPrep gradient centrifugation. Endogenous RGS16 in rat liver plasma membrane partitioned to DRM fractions 1 and 2 (Fig. 4A). G{alpha}i was also found in DRM fraction 1. Na+/K+-ATPase, a plasma membrane protein not found in lipid rafts (30), was in higher density fractions 7-9. RGS16 after transfection in COS cells was also found in the DRM fractions (Fig. 4B). Caveolin, a lipid raft protein, and G{alpha}i were in DRM fractions 1 and 2, and Na+/K+-ATPase was in higher density fractions 6-9 in these cells. The RGS16 in the detergent-soluble fractions would contain not only any of the membrane-bound RGS16 not in lipid rafts, but also a significant amount (about 50% of the total) of both the WT and C2A/C12A mutant found in the cytosolic fraction after transfection (data not shown) (9). The nonpalmitoylated, C2A/C12A mutant of RGS16 showed a shift away from the DRM fraction to intermediate fractions 2-5. This result suggests that palmitoylation was important in targeting RGS16 to lipid rafts. The plasma membrane may contain multiple microdomains with different densities after detergent treatment and gradient centrifugation (30) and the nonpalmitoylated C2A/C12A mutant may localize to such a domain.

We then tested the role of lipid rafts for RGS16 function because the decrease in GAP activity of the nonpalmitoylated C2A/C12A mutant could be due to a decrease of this mutant in the lipid rafts. We disrupted lipid rafts by treating cells with methyl-{beta}-cyclodextrin (CD), a cholesterol-binding agent that depletes cellular cholesterol. In HEK293 cells, treatment with 10 mM CD for 30 min depleted the cellular cholesterol by 42 ± 2% (mean ± S.E. of three experiments). WT RGS16 and G{alpha}i were completely shifted from the DRM fractions, and caveolin showed a partial displacement (Fig. 5A). The 5-HT-induced GTPase activity in the membranes of HEK293 cells expressing the 5-HT1A/G{alpha}o1 fusion protein was determined after CD treatment and found to be significantly increased compared to cells without CD treatment (Fig. 5B). A possible explanation for this increase is an improvement of endogenous RGS protein activity. However, further studies in which endogenous RGS activity is blocked will be needed to clarify this issue. Despite the increase observed with CD treatment alone, co-expression of RGS16 led to a similar degree of enhancement in GTPase activity for cells treated with or without cyclodextrin (Fig. 5B). This result indicates that the GAP activity of RGS16 remained intact in membranes after disruption of lipid rafts.



View larger version (21K):
[in this window]
[in a new window]
 
FIG. 5.
Disruption of lipid rafts by methyl-{beta}-cyclodextrin treatment. HEK293 cells stably expressing the 5-HT1A/G{alpha}o1 fusion protein were transiently transfected with the vector alone or the cDNA encoding RGS16. The cells were pretreated with pertussis toxin, and 2 days after the transfection, the cells were treated with medium alone or with 10 mM CD for 30 min. Cells were prepared for DRM partitioning and immunoblotting as described in the legend to Fig. 4 (A), or cell membranes were prepared for agonist-stimulated steady-state GTPase activity as determined after addition of the indicated concentrations of 5-HT and incubation for 20 min at 37 °C (B). Values represent the mean ± S.E. of four independent experiments. The arrowheads point to RGS16.

 

We determined the DRM partitioning of the 5-HT1A/G{alpha}o1 fusion protein to further explore the role of lipid rafts in RGS16 function. The fusion protein was exclusively found in detergent-soluble fractions 7-9, while the lipid raft proteins, caveolin and G{alpha}i, were in DRM fraction 1 (Fig. 6A). The WT RGS16 was distributed to DRM fraction 1 and the detergent-soluble fractions. Thus, the inability of the nonpalmitoylated, C2A/C12A mutant of RGS16 to increase the GTPase activity of the 5-HT1A/G{alpha}o1 fusion protein compared with the WT RGS16 was unlikely to be solely because of mistargeting away from lipid rafts, because the 5-HT1A/G{alpha}o1 fusion protein was not in the lipid raft fraction. Taken together, the results with cyclodextrin treatment and DRM fractionation suggest that RGS16 did not require co-localization with its cognate G{alpha} subunit in a lipid raft to act as a GAP in cell membranes.



View larger version (20K):
[in this window]
[in a new window]
 
FIG. 6.
DRM partitioning of the 5-HT1A/G{alpha}o1 fusion protein and protein acyltransferase activity. HEK293 cells stably expressing the 5-HT1A/G{alpha}o1 fusion protein alone (B) or transiently transfected with the WT RGS16 (A) were treated with cold, Triton X-100 detergent and separated by gradient centrifugation. Nine (A) or six (B) fractions were taken (number 1 was from the top) for immunoblotting with an antibody to the 5-HT1A receptor used to detect the fusion protein, the CT-265 antiserum to RGS16, and the appropriate antibodies to detect G{alpha}i, caveolin, and Na+/K+-ATPase. B, PAT activity was determined by incubating 10 µg of purified RGS16 with 3 µg of protein from the cell fractions in a buffer containing [3H]palmitate. The mixture was separated by SDS-PAGE, and PAT activity was determined by fluorography.

 

Lipid rafts are the home to many acylated proteins (16, 17). A recent report showed an enrichment of PAT activity in a low density membrane fraction (23). We tested the PAT activity of the DRM and detergent-soluble fractions after OptiPrep gradient centrifugation of the HEK293 cells stably expressing the 5-HT1A/G{alpha}o1 fusion protein. As in other experiments, caveolin and G{alpha}i were in the lower density fractions 1-2 and Na+/K+-ATPase in the higher density fractions 4-6. The fractions were incubated with [3H]palmitate and purified RGS16 as the substrate, and the level of tritium incorporation into RGS16 was determined by fluorography (Fig. 6B). Staining of the gels with Coomassie Blue showed equivalent amounts of RGS16 in each lane (data not shown). An increase in tritium incorporation was seen in the 30-kDa band for samples incubated with fractions 1 and 2. In agreement with a previous study using different fractionation methods (23), these results show that PAT activity was enriched in membrane fractions containing proteins found in lipid rafts.

Palmitoylation of an Internal Cysteine Residue—We investigated whether another defect was present in the C2A/C12A mutant of RGS16 to explain its diminished GAP activity. Another role for palmitoylation on Cys-2 and Cys-12 could be palmitoylation of an internal cysteine residue that is conserved within the RGS box of many RGS proteins (Table I). Palmitoylation on Cys-95 in RGS4 and Cys-66 in RGS10 modifies the GAP activity of these proteins (13). RGS4 requires Cys-2 and Cys-12 for autopalmitoylation of Cys-95, and [3H]palmitate incorporation on Cys-2 and Cys-12 precedes that on Cys-95 (13). COS cells expressing the WT RGS16 or C2A/C12A mutant after transient transfection were metabolically labeled with [3H]palmitate, and the RGS16 proteins in the particulate fractions were immunoprecipitated with the CT-265 antiserum. Both RGS16 WT and C2A/C12A were expressed to a similar degree in the membrane fractions (data not shown). Tritium incorporation was seen in a 30-kDa band for the cells expressing RGS16 WT, but not for the RGS16 (C2A/C12A)-expressing cells (Fig. 7A).


View this table:
[in this window]
[in a new window]
 
TABLE I

Mammalian RGS proteins with a cysteine residue in the {alpha}4 helix of the RGS box

The sequence of the {alpha}4 helix for RGS16 is EENLEFWLACEEFK. The underlined residues are in contact with the switch region of G{alpha}i1 in the crystal structure of the RGS4-G{alpha}i1 complex (44). The RGS sequences were obtained from Refs. 4, 5, and 46, 47, 48.

 


View larger version (26K):
[in this window]
[in a new window]
 
FIG. 7.
[3H]Palmitate incorporation into RGS16. A, COS cells were transfected with vector alone or with the cDNAs for the WT or C2A/C12A mutant of RGS16. Two days after transfection, the cells were incubated with [3H]palmitate, homogenized, and separated into particulate and soluble fractions. The RGS16 proteins in the particulate fractions underwent immunoprecipitation with the CT-265 antiserum to RGS16 separation by SDS-PAGE and fluorography with exposure to MS film for 7 days. B and C, COS cells were transfected with vector alone or with the cDNAs for the HA-tagged WT or C98A mutants of RGS16. Two days after transfection, the cells were incubated with [35S]methionine (B) or [3H]palmitate (C), homogenized, and separated into particulate and soluble fractions. The RGS16 proteins in the particulate fractions underwent immunoprecipitation with the HA antiserum to RGS16 and the immunoprecipitates were treated with or without the protease, clostripain (clos.) for 2 h at room temperature. The reaction was stopped by the addition of sample buffer and the proteins separated by SDS-PAGE using 10-20% Tricine gels and prepared for fluorography and exposure to film for 2 (B) or 7 (C) days. The arrow indicates the full-length RGS16 and the arrowhead indicates the 5-kDa band. The molecular mass markers in kDa are shown to the left.

 

We tested for an additional site in RGS16 that was critical for palmitoylation by transfecting COS cells with vector alone or with the cDNAs for the WT RGS16 or a mutant in which Cys-98 is changed to alanine, and metabolically labeling with [3H]palmitate or [35S]methionine. The C2A/C12A mutant was not used in these experiments because it did not incorporate [3H]palmitate after metabolic labeling in cells (Fig. 7A). RGS16 was immunoprecipitated and treated with the protease, clostripain, which cleaves peptides after arginine residues. Complete cleavage of RGS16 with clostripain results in a 4926-dalton fragment, the peptide from residues 64 to 105 that contains Cys-98 as the only cysteine residue, and in smaller fragments (3390 to 409 daltons). Immunoprecipitation of the [35S]methionine-labeled fraction showed that both of the proteins were expressed and proteolyzed to the same degree (Fig. 7B). The 4926-dalton fragment does not contain any methionine residues and would not be detected by this method. Separation by SDS-PAGE of the [3H]palmitate-labeled peptides after clostripain treatment, followed by fluorography, showed a band at about 5 kDa for the WT RGS16-transfected cells that was not present in the vector or C98A-transfected cells (Fig. 7C). We often saw a tritium-labeled band at about 16 kDa that most likely represents a degradation product of RGS16 because it was not seen in the vector-transfected cells. This result suggests that WT RGS16 undergoes palmitoylation on the Cys-98 residue and that this modification requires Cys-2 and Cys-12. The functional effects of palmitoylation on Cys-98 are reported in the accompanying article (24).


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Regulation of G protein signaling occurs at many steps during the GTPase activation cycle. RGS proteins accelerate the GTP hydrolysis of G{alpha} subunits to return them to their basal state. For RGS proteins to work, they need to be at the cytoplasmic face of the plasma membrane where they can bind to the G{alpha} subunit in its transition state of GTP hydrolysis. We found that cysteine residues on the amino terminus of RGS16 were important for accelerating the GTPase activity of the G{alpha} subunit at the membrane, for targeting RGS16 to lipid rafts, and for palmitoylation of an internal cysteine residue. Based on these results, we propose a new function of protein palmitoylation: the targeting of proteins to lipid rafts that are enriched in palmitoyltransferase activity to allow palmitoylation of poorly accessible cysteine residues.

Plasma Membrane Targeting—Previous studies with RGS16 and a closely related protein, RGS4, showed that an amphipathic {alpha} helix near the amino terminus is a key determinant in plasma membrane targeting for these proteins in yeast (14, 39). Mutation of hydrophobic and basic residues in this amphipathic helix encompassing the first 33 amino acids, decreases the plasma membrane localization and biologic activity of these proteins (14, 39), whereas mutation of palmitoylation sites had a minor effect on localization (12, 14). In addition to the amphipathic {alpha} helix, the amino-terminal end of the RGS domain of RGS16 interacts with an integral membrane protein, MIR16, found at the plasma membrane in liver cells (40). Sites for palmitoylation are often found near membrane targeting signals (41). A two-signal model of membrane targeting predicts that proteins first find a docking partner at the membrane and then undergo palmitoylation that locks the protein in place (42, 43). The utility of palmitoylation for membrane targeting is then dependent on the affinity of the targeting signal for the binding partner. For RGS16, the loss of palmitoylation did not significantly change the plasma membrane localization as detected by fractionation studies and electron microscopy in mammalian cells. Therefore, the amphipathic {alpha} helix and possibly other targeting signals are adequate to keep RGS16 at the plasma membrane without palmitoylation stabilizing the binding. The significant amount of RGS16 found in the cytosolic fraction after overexpression may be because of a saturation of RGS16 membrane binding sites.

Lipid Raft Targeting and RGS16 Function—Lipid rafts contain signaling proteins and are critical for a number of signaling pathways (18, 19, 20). We found RGS16 in lipid rafts and the amino-terminal cysteine residues were necessary for this targeting. A simple explanation for the poor signaling function of the C2A/C12A mutant would be mistargeting from the lipid rafts. Yet, the GAP activity of RGS16 was intact after disruption of lipid rafts by cholesterol depletion. In addition, co-localization of RGS16 and the G{alpha} subunit in lipid rafts was not important because in these studies the G{alpha} subunit fused to the receptor was not in lipid rafts. Besides, it is not clear whether the lipid raft localization for RGS16 would facilitate or inhibit its activity. G{alpha}i and G{alpha}q, the G proteins that bind RGS16, are found in DRM fractions (37, 38), but RGS proteins act on the nonpalmitoylated forms of G{alpha} subunits (15). Mutations that prevent palmitoylation lead to a loss of DRM partitioning for G{alpha}i (16, 37), suggesting that G{alpha} subunits may leave lipid rafts upon depalmitoylation during the thioacylation cycle, although we are unaware of reports on the lipid raft localization of G{alpha} subunits during the activation cycle. Whereas the 5HT1A/G{alpha}o1 fusion protein is an artificial binding partner for RGS16, its nonraft localization is likely to mimic the localization of the nonpalmitoylated forms of G{alpha} subunits when they bind to RGS proteins. Therefore, lipid raft localization of RGS16 does not appear critical for its GAP activity by placing RGS16 in proximity of the G{alpha} subunits. Instead, our data suggest that lipid raft localization may be necessary for palmitoylation of an internal cysteine residue.

Palmitoylation on a Cysteine in the RGS Box of RGS16— Palmitoylation occurs at the membrane on cysteine residues that must be in close proximity and accessible to the membrane-bound protein acyltransferase. For that reason, palmitoylation sites are often near the ends of proteins, but palmitoylation does not require a consensus sequence on the protein, so any cysteine residue can potentially undergo palmitoylation. Cys-98 in RGS16 is on the {alpha}4 helix in a highly conserved area six residues from the G{alpha} binding sites based on the crystal structure of the RGS box of the homologous protein, RGS4, binding to G{alpha}i (44). Hydrophobic residues surround Cys-98 in the {alpha}4 helix and in the adjacent {alpha}5 helix. A space-filling model of RGS4 and G{alpha}i show that this conserved cysteine residue is buried in the structure except for one surface that is about 120 degrees away from the presumed membrane-facing surface of the complex (Fig. 8). This orientation of the cysteine away from the membrane may explain our and others finding that mutation of Cys-2 and Cys-12 alone blocks [3H]palmitate incorporation because the thioester group on Cys-98 is not readily accessible to PAT and the membrane. Computer modeling of the amino terminus of RGS16 shows that it shares structural homology to domains on CTP-phosphocholine cytidylyltransferase and prostaglandin H synthase that intercalate into the membrane (14). Binding of RGS4 to phospholipids vesicles containing receptors and G proteins is a slow, multistep process (45). A possible sequence of events for the interactions of RGS16 with the membrane is that the amino terminus of RGS16 may be embed in the membrane and lead to palmitoylation of Cys-2 and Cys-12. Acylation then stabilizes the membrane binding and targets RGS16 to lipid rafts, which are enriched in PAT activity. Within the environment of increased PAT activity, rotation of the {alpha}4 helix or the whole protein that exposes Cys-98 to the membrane could lead to its palmitoylation. In the following article (24), we show that palmitoylation on Cys-98 greatly enhanced the GAP activity of RGS16. RGS16 does not quickly take a seat at the membrane, but instead nestles in until it finds a comfortable position to optimally interact with the G{alpha} subunit.



View larger version (61K):
[in this window]
[in a new window]
 
FIG. 8.
Structure of the RGS box binding G{alpha}i. A space filling model of the RGS box of RGS4 binding G{alpha}i1 was created using the Cn3D software (www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml) based on the crystal structure of this complex (44). A, the presumed membrane-facing surface of the complex (49). B, rotation by about 120° through the vertical axis of the structure shown in panel A. Cys-95, which corresponds to Cys-98 in RGS16, is only visible on this surface. G{alpha}i1 is shown in light gray, the RGS box of RGS4 in dark green, the amino- and carboxyl-terminal ends of G{alpha}i1 in magenta, the amino-terminal end of the RGS box, which starts at residue 51, in aqua, and Cys-95 in light orange.

 

Acylation has many roles for protein function including membrane attachment, plasma membrane and lipid raft targeting, and conformational changes. The function of palmitoylation, like phosphorylation, another reversible protein modification, is likely to be specific for each protein. For RGS16, palmitoylation may have two roles: 1) amino-terminal palmitoylation directs the proteins to lipid rafts to allow palmitoylation of an internal cysteine residue; and 2) palmitoylation of this internal cysteine residue increases the GAP activity of the protein through changes in the conformation or orientation at the membrane. In the future, we may find even more functions of palmitoylation in protein regulation.


    FOOTNOTES
 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ Both authors contributed equally to this work. Back

§§ To whom correspondence should be addressed: Bldg. 10, Rm. 9C101, National Institutes of Health, Bethesda, MD 20892-1802. Tel.: 301-496-8711; Fax: 301-496-0200; E-mail: tlzj{at}helix.nih.gov.

1 The abbreviations used are: RGS, regulator of G protein signaling; 5-HT, 5-hydroxytryptamine; 5-HT1a/Gao1, fusion protein of the 5-HT receptor subtype 1A with the mutant (C361G) G{alpha}o1 protein; PBS, phosphate-buffered saline; CD, methyl-{beta}-cyclodextrin; GAP, GTPase activating protein; WT, wild type; DRM, detergent-resistant membranes; HA, hemagglutinin; PAT, protein acyltransferase; HEK, human embryonic kidney; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; AMP-PNP, adenosine 5'-({beta},{gamma}-imino)triphosphate; HB, homogenization buffer. Back


    ACKNOWLEDGMENTS
 
We thank Drs. Melvin I. Simon for the CT-265 antiserum, Samuel W. Cushman for the rat livers, and Peter S. Backlund for technical advice.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Hamm, H. E. (1998) J. Biol. Chem. 273, 669-672[Free Full Text]
  2. Gilman, A. G. (1987) Annu. Rev. Biochem. 56, 615-649[CrossRef][Medline] [Order article via Infotrieve]
  3. Ross, E. M., and Wilkie, T. M. (2000) Annu. Rev. Biochem. 69, 795-827[CrossRef][Medline] [Order article via Infotrieve]
  4. De Vries, L., Zheng, B., Fischer, T., Elenko, E., and Farquhar, M. G. (2000) Annu. Rev. Pharmacol. Toxicol. 40, 235-271[CrossRef][Medline] [Order article via Infotrieve]
  5. Siderovski, D. P., Strockbine, B., and Behe, C. I. (1999) Crit. Rev. Biochem. Mol. Biol. 34, 215-251[Abstract/Free Full Text]
  6. Chen, C. K., Wieland, T., and Simon, M. I. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 12885-12889[Abstract/Free Full Text]
  7. Chen, C., Zheng, B., Han, J., and Lin, S. C. (1997) J. Biol. Chem. 272, 8679-8685[Abstract/Free Full Text]
  8. Rose, J. J., Taylor, J. B., Shi, J., Cockett, M. I., Jones, P. G., and Hepler, J. R. (2000) J. Neurochem. 75, 2103-2112[CrossRef][Medline] [Order article via Infotrieve]
  9. Druey, K. M., Ugur, O., Caron, J. M., Chen, C. K., Backlund, P. S., and Jones, T. L. Z. (1999) J. Biol. Chem. 274, 18836-18842[Abstract/Free Full Text]
  10. De Vries, L., Elenko, E., Hubler, L., Jones, T. L. Z., and Farquhar, M. G. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 15203-15208[Abstract/Free Full Text]
  11. Castro-Fernandez, C., Janovick, J. A., Brothers, S. P., Fisher, R. A., Ji, T. H., and Conn, P. M. (2002) Endocrinology 143, 1310-1317[Abstract/Free Full Text]
  12. Srinivasa, S. P., Bernstein, L. S., Blumer, K. J., and Linder, M. E. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5584-5589[Abstract/Free Full Text]
  13. Tu, Y., Popov, S., Slaughter, C., and Ross, E. M. (1999) J. Biol. Chem. 274, 38260-38267[Abstract/Free Full Text]
  14. Chen, C., Seow, K. T., Guo, K., Yaw, L. P., and Lin, S. C. (1999) J. Biol. Chem. 274, 19799-19806[Abstract/Free Full Text]
  15. Tu, Y., Wang, J., and Ross, E. M. (1997) Science 278, 1132-1135[Abstract/Free Full Text]
  16. Moffett, S., Brown, D. A., and Linder, M. E. (2000) J. Biol. Chem. 275, 2191-2198[Abstract/Free Full Text]
  17. Melkonian, K. A., Ostermeyer, A. G., Chen, J. Z., Roth, M. G., and Brown, D. A. (1999) J. Biol. Chem. 274, 3910-3917[Abstract/Free Full Text]
  18. Simons, K., and Toomre, D. (2000) Nat. Rev. Mol. Cell. Biol. 1, 31-39[CrossRef][Medline] [Order article via Infotrieve]
  19. Shaul, P. W., and Anderson, R. G. W. (1998) Am. J. Physiol. 275, L843-851[Medline] [Order article via Infotrieve]
  20. Brown, D. A., and London, E. (2000) J. Biol. Chem. 275, 17221-17224[Free Full Text]
  21. Miura, Y., Hanada, K., and Jones, T. L. Z. (2001) Biochemistry 40, 15418-15423[CrossRef][Medline] [Order article via Infotrieve]
  22. Nair, K. S., Balasubramanian, N., and Slepak, V. Z. (2002) Curr. Biol. 12, 421-425[CrossRef][Medline] [Order article via Infotrieve]
  23. Dunphy, J. T., Greentree, W. K., and Linder, M. E. (2001) J. Biol. Chem. 276, 43300-43304[Abstract/Free Full Text]
  24. Osterhout, J. L., Waheed, A. A., Hiol, A., Ward, R. J., Davey, P. C., Nini, L., Wang, J., Milligan, G., Jones, T. L. Z., and Druey, K. M. (2003) J. Biol. Chem. 278, 19309-19316[Abstract/Free Full Text]
  25. Kellett, E., Carr, I. C., and Milligan, G. (1999) Mol. Pharmacol. 56, 684-692[Abstract/Free Full Text]
  26. Jones, T. L. Z., Simonds, W. F., Merendino, J. J., Jr., Brann, M. R., and Spiegel, A. M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 568-572[Abstract]
  27. Goldsmith, P., Gierschik, P., Milligan, G., Unson, C. G., Vinitsky, R., Malech, H. L., and Spiegel, A. M. (1987) J. Biol. Chem. 262, 14683-14688[Abstract/Free Full Text]
  28. Brown, W. J., and Farquhar, M. G. (1989) Methods Cell Biol. 31, 553-569[Medline] [Order article via Infotrieve]
  29. Waheed, A. A., and Jones, T. L. Z. (2002) J. Biol. Chem. 277, 32409-32412[Abstract/Free Full Text]
  30. Lindwasser, O. W., and Resh, M. D. (2001) J. Virol. 75, 7913-7924[Abstract/Free Full Text]
  31. Caron, J. M. (1997) Mol. Biol. Cell 8, 621-636[Abstract]
  32. Milligan, G. (2000) Trends Pharmacol. Sci. 21, 24-28[CrossRef][Medline] [Order article via Infotrieve]
  33. Bhattacharyya, R., and Wedegaertner, P. B. (2000) J. Biol. Chem. 275, 14992-14999[Abstract/Free Full Text]
  34. Morales, J., Fishburn, C. S., Wilson, P. T., and Bourne, H. R. (1998) Mol. Biol. Cell 9, 1-14[Free Full Text]
  35. Hancock, J. F., Paterson, H., and Marshall, C. J. (1990) Cell 63, 133-139[Medline] [Order article via Infotrieve]
  36. Wolven, A., Okamura, H., Rosenblatt, Y., and Resh, M. D. (1997) Mol. Biol. Cell 8, 1159-1173[Abstract]
  37. Galbiati, F., Volonte, D., Meani, D., Milligan, G., Lublin, D. M., Lisanti, M. P., and Parenti, M. (1999) J. Biol. Chem. 274, 5843-5850[Abstract/Free Full Text]
  38. Pike, L. J., and Miller, J. M. (1998) J. Biol. Chem. 273, 22298-22304[Abstract/Free Full Text]
  39. Bernstein, L. S., Grillo, A. A., Loranger, S. S., and Linder, M. E. (2000) J. Biol. Chem. 275, 18520-18526[Abstract/Free Full Text]
  40. Zheng, B., Chen, D., and Farquhar, M. G. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 3999-4004[Abstract/Free Full Text]
  41. Ugur, O., and Jones, T. L. Z. (2000) Mol. Biol. Cell 11, 1421-1432[Abstract/Free Full Text]
  42. Dunphy, J. T., and Linder, M. E. (1998) Biochim. Biophys. Acta 1436, 245-261[Medline] [Order article via Infotrieve]
  43. Wedegaertner, P. B. (1998) Biol. Signals Recept. 7, 125-135[Medline] [Order article via Infotrieve]
  44. Tesmer, J. J., Berman, D. M., Gilman, A. G., and Sprang, S. R. (1997) Cell 89, 251-261[Medline] [Order article via Infotrieve]
  45. Tu, Y., Woodson, J., and Ross, E. M. (2001) J. Biol. Chem. 276, 20160-20166[Abstract/Free Full Text]
  46. Zheng, B., Ma, Y. C., Ostrom, R. S., Lavoie, C., Gill, G. N., Insel, P. A., Huang, X. Y., and Farquhar, M. G. (2001) Science 294, 1939-1942[Abstract/Free Full Text]
  47. Kourlas, P. J., Strout, M. P., Becknell, B., Veronese, M. L., Croce, C. M., Theil, K. S., Krahe, R., Ruutu, T., Knuutila, S., Bloomfield, C. D., and Caligiuri, M. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 2145-2150[Abstract/Free Full Text]
  48. Park, I. K., Klug, C. A., Li, K., Jerabek, L., Li, L., Nanamori, M., Neubig, R. R., Hood, L., Weissman, I. L., and Clarke, M. F. (2001) J. Biol. Chem. 276, 915-923[Abstract/Free Full Text]
  49. Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P., Hamm, H. E., and Sigler, P. B. (1996) Nature 379, 311-319[CrossRef][Medline] [Order article via Infotrieve]